Related references
Note: Only part of the references are listed.Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer
Paul Dowling et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Chiara Lazzari et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging
A. -M. C. Dingemans et al.
ANNALS OF ONCOLOGY (2011)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
Roy S. Herbst et al.
LANCET (2011)
Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome
David Venet et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients
Christine H. Chung et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer
Joline S. W. Lind et al.
CLINICAL CANCER RESEARCH (2010)
Bevacizumab/erlotinib (BEER) as first-line treatment for untreated, advanced non-squamous non-small cell lung cancer (NSNSCLC)
W. L. Akerley et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503
Joseph M. Amann et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
David P. Carbone et al.
LUNG CANCER (2010)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors
L. V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study
Fumiko Taguchi et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio
M Kokubun et al.
CLINICA CHIMICA ACTA (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The role of surgery in N2 non-small cell lung cancer
MM DeCamp et al.
CLINICAL CANCER RESEARCH (2005)
Angiogenesis and lung cancer: Prognostic and therapeutic implications
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Proteomic patterns of tumour subsets in non-small-cell lung cancer
K Yanagisawa et al.
LANCET (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
